Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

PURPOSE Retinal ganglion cell (RGC) loss occurs in response to increased intraocular pressure (IOP) and/or retinal ischemia in glaucoma and leads to impairment of vision. This study was undertaken to test the efficacy of erythropoietin (EPO) in providing neuroprotection to RGCs in vivo. METHODS The neuroprotective effects of EPO were studied in the DBA/2J mouse model of glaucoma. Mice were intraperitoneally injected with control substances or various doses of EPO, starting at the age of 6 months and continuing for an additional 2, 4, or 6 months. RGCs were labeled retrogradely by a gold tracer. IOP was measured with a microelectric-mechanical system, and EPO receptor (EPOR) expression was detected by immunohistochemistry. Axonal death in the optic nerve was quantified by para-phenylenediamine staining, and a complete blood count system was used to measure the number of erythrocytes. RESULTS In DBA/2J mice, the average number of viable RGCs significantly decreased from 4 months to 10 months, with an inverse correlation between the number of dead optic nerve axons and viable RGCs. Treatment with EPO at doses of 3000, 6000, and 12,000 U/kg body weight per week all prevented significant RGC loss, compared with untreated DBA/2J control animals. EPO effects were similar to those of memantine, a known neuroprotective agent. IOP, in contrast, was unchanged by both EPO and memantine. Finally, EPOR was expressed in the RGC layer in both DBA/2J and C57BL/6J mice. CONCLUSIONS EPO promoted RGC survival in DBA/2J glaucomatous mice without affecting IOP. These results suggest that EPO may be a potential therapeutic neuroprotectant in glaucoma.

[1]  R. Masland,et al.  Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice , 2005, The Journal of cell biology.

[2]  S. Masuda,et al.  Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. , 2005, The New England journal of medicine.

[3]  S. Isenmann,et al.  Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation , 2005, Molecular and Cellular Neuroscience.

[4]  H. Yamashita,et al.  Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells , 2005, Brain Research.

[5]  L. Jönsson.  Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. , 2005, The American journal of geriatric pharmacotherapy.

[6]  P. Ghezzi,et al.  Erythropoietin protects primary hippocampal neurons increasing the expression of brain‐derived neurotrophic factor , 2005, Journal of neurochemistry.

[7]  David A. Lee,et al.  Glaucoma and its treatment: a review. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  M. Gassmann,et al.  Erythropoietin Protects from Axotomy-induced Degeneration of Retinal Ganglion Cells by Activating Erk-1/-2 Retrograde Labeling of Rgcs Inhibition of Erk-1/2 and Phosphatidyl Inositol-3′ Kinase (pi3k)/akt Pathways Immunohistochemical Detection of Epo Receptor Erk-1/-2 and Akt Signaling Are Increased, , 2022 .

[9]  M. Forbes,et al.  Intravitreal Administration of Erythropoietin and Preservation of Retinal Ganglion Cells in an Experimental Rat Model of Glaucoma , 2005, Current eye research.

[10]  C. Stadelmann,et al.  Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis , 2004, Cell Death and Differentiation.

[11]  M. Herrmann,et al.  Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease , 2004, Metabolic Brain Disease.

[12]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[13]  P. Carmeliet,et al.  VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[14]  M. Moskowitz,et al.  Targeting eNOS for stroke protection , 2004, Trends in Neurosciences.

[15]  H. Ehrenreich,et al.  Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. , 2004, Investigative ophthalmology & visual science.

[16]  Eberhart Zrenner,et al.  Retinal neurodegeneration in the DBA/2J mouse—a model for ocular hypertension , 2004, Acta Neuropathologica.

[17]  Robert N Weinreb,et al.  Aqueous humor dynamics in mice. , 2003, Investigative ophthalmology & visual science.

[18]  M. Weiss,et al.  New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. , 2003, The oncologist.

[19]  Richard S. Smith,et al.  Modification of Ocular Defects in Mouse Developmental Glaucoma Models by Tyrosinase , 2003, Science.

[20]  T. Lappin.  The cellular biology of erythropoietin receptors. , 2003, The oncologist.

[21]  S. P. Becerra,et al.  Erythropoietin--an endogenous retinal survival factor. , 2002, The New England journal of medicine.

[22]  P. Johnston,et al.  EPO's Alter Ego: Erythropoietin Has Multiple Actions , 2002, Stem cells.

[23]  M. Buemi,et al.  Erythropoietin and the brain: from neurodevelopment to neuroprotection. , 2002, Clinical science.

[24]  A. Piccoli,et al.  Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. , 2002, Journal of nephrology.

[25]  David Zurakowski,et al.  Effects of anti-glaucoma medications on gangion cell survival: the DBA/2J mouse model , 2002, Vision Research.

[26]  D. Rosenbaum,et al.  Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Stefánsson,et al.  The impact of ocular blood flow in glaucoma , 2002, Progress in Retinal and Eye Research.

[28]  C. Grimm,et al.  HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration , 2002, Nature Medicine.

[29]  P. Rosenstiel,et al.  Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. , 2002, Investigative ophthalmology & visual science.

[30]  P. Mróz,et al.  Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  Richard S. Smith,et al.  Posterior Segment and Orbit , 2001 .

[32]  N. Miller,et al.  Optic nerve protection, regeneration, and repair in the 21st century: LVIII Edward Jackson Memorial lecture. , 2001, American journal of ophthalmology.

[33]  Stuart A. Lipton,et al.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades , 2001, Nature.

[34]  L. Kagemann,et al.  Simultaneous management of blood flow and IOP in glaucoma. , 2001, Acta ophthalmologica Scandinavica.

[35]  H. Ehrenreich,et al.  Erythropoietin – a novel concept for neuroprotection , 2001, European Archives of Psychiatry and Clinical Neuroscience.

[36]  S. Juul,et al.  The Biology of Erythropoietin in the Central Nervous System and Its Neurotrophic and Neuroprotective Potential , 2001, Neonatology.

[37]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  F. Kuralay,et al.  Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production , 2001, Neuroscience Letters.

[39]  Michael G. Anderson,et al.  Genetic modification of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice , 2001, BMC Genetics.

[40]  E. Yoles,et al.  RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. , 2000, Investigative ophthalmology & visual science.

[41]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Semenza,et al.  Protection from Oxidative Stress–Induced Apoptosis in Cortical Neuronal Cultures by Iron Chelators Is Associated with Enhanced DNA Binding of Hypoxia-Inducible Factor-1 and ATF-1/CREB and Increased Expression of Glycolytic Enzymes, p21waf1/cip1, and Erythropoietin , 1999, The Journal of Neuroscience.

[43]  Michael G. Anderson,et al.  Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice , 1999, Nature Genetics.

[44]  H. Quigley,et al.  Neuronal death in glaucoma , 1999, Progress in Retinal and Eye Research.

[45]  T H Roderick,et al.  Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. , 1998, Investigative ophthalmology & visual science.

[46]  E. Morishita,et al.  In vivo evidence that erythropoietin protects neurons from ischemic damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  E. Morishita,et al.  Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death , 1996, Neuroscience.

[48]  S. Sharma,et al.  Programmed cell death of retinal ganglion cells during experimental glaucoma. , 1995, Experimental eye research.

[49]  D. Zack,et al.  Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. , 1995, Investigative ophthalmology & visual science.

[50]  H. Lodish,et al.  Structure, function, and activation of the erythropoietin receptor. , 1993, Blood.

[51]  C. Stabile.  [Recombinant human erythropoietin]. , 1992, Revista da Associacao Medica Brasileira.

[52]  S. Flitman.  Current Pharmacotherapy for Alzheimer ’ s Disease , 2006 .

[53]  K. Genc,et al.  Erythropoietin as a novel neuroprotectant. , 2004, Restorative neurology and neuroscience.

[54]  Janey L. Wiggs,et al.  Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice , 2002, Nature Genetics.

[55]  P. Mayeux,et al.  Erythropoietin (Epo) receptor and Epo mimetics. , 1999, Advances in nephrology from the Necker Hospital.